A	B	C
1	Main
2		Brand	Tecentriq, fka RG7446
3		Generic	atezolizumab
4		Indication	ES-SCLC (CHMP recommended approval)
5			SCLC accounts for 15% of all lung cancer, with 70% in extensive stage. 1.76m deaths every year due to lung cancer, WW.
6		MOA	PD-1 mab
7		Clinical Trials
8			Phase III "IMpower133" n=403 1L ES-SCLC
9			Carboplatin+Etoposide vs. Tecentriq+carboplatin+etoposide
10			median OS 12.3 vs. 10.3 months, HR=0.70
11			median PFS 5.2 vs. 4.3 months, HR=0.77
12
13			Phase III "IMpower130" n=723 1L nsNSCLC
14			no EGFRm or ALK+, stage IV, 2:1 randomization
15			Tecentriq+carboplatin+nab-paclitaxel vs. carboplatin+nab-paclitaxel
16			median OS 18.6 vs. 13.9 months, HR=0.79, p=0.033
17			median PFS 7.0 vs. 5.5 months, HR=0.64, p<0.0001
18			49.2% ORR vs. 31.9%, mDOR 8.4 months vs. 6.1 months